FDA approves Strattera for ADHD maintenance

The FDA has approved Strattera (atomoxetine HCl capsules, from Eli Lilly) for maintenance treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ≥6 years of age. A clinical trial of 604 patients aged 6-15 years, showed that Strattera was superior to placebo in maintaining continuous efficacy, as measured by the ADHD Rating Scale (ADHD-RS). At the end of the trial, patients taking Strattera had lower relapse rates (2.5%) as compared to patients taking placebo (12.2%).

For more information call (800) LILLY-RX or visit www.strattera.com.